Early clinical trial data show gene therapy reversing sickle cell anemia

December 03, 2018

CINCINNATI-- After over a decade of preclinical research and development, a new gene therapy treatment for Sickle Cell Anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.

Preliminary data from a pilot Phase 1-2 clinical trial testing the gene-addition therapy were presented Dec. 3 at the American Society of Hematology's (ASH) annual meeting in San Diego by principal investigator Punam Malik, MD. She is a physician-scientist at the Cincinnati Children's Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center. Malik called the data promising.

"One year after treatment of our first patient, and six months after treatment of our second patient, both have seen a remarkable improvement in the quality of life due to remarkable reduction in disease symptoms. This includes near elimination of chronic pain and sickling events and improved anemia," Malik said. "Although it's still early post-treatment, these preliminary results are quite promising. If sustained this therapy will provide a transportable, safe and feasible gene therapy for all SCA patients."

SCA is a painful, inherited disease where blood cells become sickle-shaped and stuck in the vascular system. It can damage vital organs and cause death.

How the Therapy Works

The gene therapy developed by Cincinnati Children's uses a modified gamma globin lentivirus vector to transfer a healthy fetal hemoglobin gene into a patient's blood stem cells (hematopoietic stem cells, HSC). The lentivirus is modified so it does not cause illness.

The therapy comes from the observation that some adults never stop producing fetal hemoglobin (HbF). This prevents red blood cell sickling when sufficient quantities of HbF are present in the body.

Normally, the fetal hemoglobin gene switches off shortly after birth. The new gene therapy approach designed by Malik and team places a fetal hemoglobin gene in the bone marrow cells that cannot switch off.

Cells are collected earlier from the SCA patient and genetically reprogrammed in a clean lab facility with the modified lentivirus vector. Then the patient's bone marrow is preconditioned with one low-dose of chemotherapy, after which the gene-corrected cells are infused back into the patient. Patients recover their blood counts within a week to 10 days and recover from the chemotherapy effects by two weeks, Malik said.

A key feature of the treatment regimen is the reduced-intensity preconditioning for patients receiving the therapy for SCA. The method is less toxic and expensive than myeloablative preconditioning normally used in bone marrow transplants, according to the researchers.

Myeloablative conditioning uses high-intensity chemotherapy to prepare a transplant patient's bone marrow for healthy gene-corrected blood stem cells (HSCs). This typically results in low blood counts and other side effects. These can include severe infections and long stays in transplant units for one or two months.

This means transplants using myeloablative conditioning have to be performed at large and sophisticated medical centers in developed parts of the world. Malik said this limits access to people in underdeveloped regions where SCA is more common, like Africa, India, the Caribbean and South America.

Reaching High-Need Regions

One goal for Malik and her colleagues is that their therapy's reduced intensity conditioning will allow it to be offered at hospitals in places like Central Africa and other underdeveloped regions of the world.

SCA affects more than 90,000 people in the United States, and millions of people worldwide have the disease, according to the researchers.

Malik said additional data from the study will tell investigators of the consistent and long-term clinical benefit of this therapy to patients with severe SCA. The trial is scheduled to treat up to 10 patients with SCA. Preclinical studies by the research team suggested the treatment allows the body to produce normal red blood cells instead of the sickle-shaped cells that define the inherited disorder.

Improved Quality of Life

Both adult patients included in the ASH presentation are 35 and 25 years old who, respectively, had gene transfer therapy 15 and 12 months ago. In the year and a half prior to receiving gene-correction therapy, both patients had more than a dozen acute sickle events per year, according to Malik. These included acute chest and pain crises, chronic pain, and required the ongoing use of oral or injectable opioids on a regular basis.

Investigators report that one year following therapy, the first patient no longer requires daily oral opioids for chronic pain and has had one acute sickle cell event. The second patient no longer uses oral opioids and has no vaso-occlusive events, where blood cells become stuck in the vascular system.
-end-
Launch of Aruvant Sciences

In an effort to accelerate the development of the therapy, Cincinnati Children's has partnered with Roivant Sciences to create Aruvant Sciences. The joint venture is focused on developing and commercializing innovative therapies for hematological conditions. Aruvant's lead candidate is RVT-1801, the gene therapy used to treat both patients in Malik's ASH presentation of early clinical trial data. Aruvant Sciences will be based in Cincinnati. Additional information can be found here.

Cincinnati Children's Hospital Medical Center

Related Chronic Pain Articles from Brightsurf:

Researchers are developing potential treatment for chronic pain
Researchers from the University of Copenhagen have developed a new way to treat chronic pain which has been tested in mice.

Molecular link between chronic pain and depression revealed
Researchers at Hokkaido University have identified the brain mechanism linking chronic pain and depression in rats.

How chikungunya virus may cause chronic joint pain
A new method for permanently marking cells infected with chikungunya virus could reveal how the virus continues to cause joint pain for months to years after the initial infection, according to a study published Aug.

Gastroesophageal reflux associated with chronic pain in temporomandibular joint
Gastroesophageal reflux (GERD) is associated with chronic, painful temporomandibular disorder -- pain in the temporomandibular joint -- and anxiety and poor sleep contribute to this association, according to a study in CMAJ.

One step closer to chronic pain relief
While effective drugs against chronic pain are not just around the corner, researchers from Aarhus University, Denmark, have succeeded in identifying a protein as a future potential target for medicinal drugs.

Gut bacteria associated with chronic pain for first time
In a paper published today in the journal Pain, a Montreal-based research team has shown, for the first time, that there are alterations in the bacteria in the gastrointestinal tracts of people with fibromyalgia.

Nearly 5.4 million cancer survivors suffer chronic pain
A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the United States.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

New target for chronic pain relief confirmed by scientists
A research group at Hiroshima University observed a potential new target for chronic pain treatment.

Menopause symptoms nearly double the risk of chronic pain
In addition to the other health conditions affected by estrogen, it has also been shown to affect pain sensitivity.

Read More: Chronic Pain News and Chronic Pain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.